Filing Flows › Lexicon Pharmaceuticals (LXRX) › R&D spending
Lexicon Pharmaceuticals (LXRX) R&D spending by quarter
Lexicon Pharmaceuticals' R&D spending was $16.2M in Q3 2026 (third quarter 2026), -7% from Q2 2026. Over the last 7 quarters it ranged from $11.3M (Q4 2025) to $18.8M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $16.2M | -7% | -14% |
| Q2 2026 | $17.4M | +37% | +11% |
| Q1 2026 | $12.8M | +13% | -17% |
| Q4 2025 | $11.3M | -40% | — |
| Q3 2025 | $18.8M | +19% | — |
| Q2 2025 | $15.7M | +3% | — |
| Q1 2025 | $15.3M | — | — |
Q3 2026 at a glance
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lexicon Pharmaceuticals' R&D spending?
Lexicon Pharmaceuticals' R&D spending was $16.2M in Q3 2026 (third quarter 2026), -7% from Q2 2026.
How has Lexicon Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $11.3M (Q4 2025) to $18.8M (Q3 2025).
Q3 2026 results → · How Lexicon Pharmaceuticals makes money →